[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumococcal-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumococcal-infections":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,68,96,123,157,187,210,236,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100641316","randomized-controlled-trial-of-text-message-to-increase-pneumococcal-vaccination-in-adults-in-chile-100641316",false,"NCT07659470","RANDOMIZED CONTROLLED TRIAL OF TEXT MESSAGE TO INCREASE PNEUMOCOCCAL VACCINATION IN ADULTS IN CHILE.","RANDOMIZED CONTROLLED TRIAL OF THE USE OF TEXT MESSAGE REMINDERS TO INCREASE PNEUMOCOCCAL VACCINATION COVERAGE IN ADULTS AGED 65 YEARS IN CHILE.","Inclusion Criteria:\n\n* Adults born during the year 1961, turning 65 years of age in 2026\n* Resident in Chile at the time of the study\n* Valid mobile phone number registered in the National Immunization Registry (RNI)\n\nExclusion Criteria:\n\n* Record of pneumococcal vaccination in the National Immunization Registry (RNI).\n* Identified as deceased in the Chilean Civil Registry and Identification Service.",true,"ALL","64 Years","65 Years",{"count":21,"type":22},43000,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this randomized controlled trial is to learn if text message reminders sent through WhatsApp increase pneumococcal vaccination coverage in adults turning 65 years old in Chile. The main questions it aims to answer are:\n\nDo text message reminders increase the proportion of adults aged 65 years who receive the pneumococcal vaccine compared to usual care? Do text message reminders increase pneumococcal vaccination coverage within the first 7 days after the message is sent? Is there an association between socioeconomic factors and pneumococcal vaccination coverage in adults aged 65 years in Chile?\n\nResearchers will compare adults who receive a text message reminder to adults who receive no reminder (usual care) to see if the reminders increase vaccination uptake.\n\nParticipants will:\n\nBe randomly assigned to receive a WhatsApp text message reminder about the pneumococcal vaccine or to receive no reminder Receive a second reminder on day 14 if they have not yet been vaccinated (intervention group only) Be followed for 6 weeks, with vaccination status checked at days 7, 21, and 42 from the start of the intervention",[28,29,30,31,32,33,34],"Pneumococcal Infections","Immunization Programs","Vaccination Coverage","Text Messaging (Intervention)","Reminder Systems","Health Promotion","Aged 65 Years or Older",[36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54],"Pneumococcal vaccine","Vaccination coverage","Text message reminder","WhatsApp","Older adults","National Immunization Program","Randomized controlled trial","Health behavior nudge","Digital health intervention","Public health","Streptococcus pneumoniae","Behavioral intervention","Vaccine uptake","Low-cost intervention","Population-based intervention","Pneumococcal polysaccharide vaccine","Immunization registry","Latin America","Chile","NOT_YET_RECRUITING","2026-06-15",{"date":58,"type":59},"2026-06-22","ACTUAL",{"date":61,"type":22},"2026-07-15",{"date":63,"type":22},"2026-10-01",{"name":65,"class":66},"Pablo Tomás Valenzuela García","OTHER",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":16,"sex":17,"minAge":75,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100642701","a-clinical-trial-of-the-13-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197tetanus-toxoid-100642701","NCT07648641","A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Phase IV Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Inclusion Criteria:\n\n* Participants in the 2-month-old (minimum 6 weeks) group from the previous Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV)\n* The legal guardian or authorized representative is willing to provide identification documents\n* The legal guardian or authorized representative has provided informed consent, voluntarily signed the informed consent form, and is able to comply with the requirements of the clinical study protocol\n* The interval since the last dose of the primary vaccination series is ≥4 years\n\nExclusion Criteria:\n\n* Failure to complete blood draws at 1 and 2 years post-vaccination\n* Administration of any pneumonia vaccine after completion of the full vaccination series\n* Body temperature ≥37.3°C\n* Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial","5 Years",{"count":77,"type":22},100,"OBSERVATIONAL","This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV), with 50 participants in each of the treatment and control groups, and who have completed blood sample collection for the 1-year and 2-year immunogenicity studies. All participants will have 3.0-3.5 mL of venous blood collected for the immunogenicity study.",[28,81,82],"Streptococcal Infections","Bacterial Infections",[84,85,28,86],"PCV13","13 valent Pneumococcal conjugate vaccine","Immune persistence","2026-06-10",{"date":56,"type":59},{"date":90,"type":22},"2026-07-01",{"date":92,"type":22},"2027-12-01",{"name":94,"class":95},"CanSino Biologics Inc.","INDUSTRY",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":67},"100413512","national-non-interventional-study-of-invasive-pneumococcal-disease-in-children-and-newborns-100413512","NCT04664556","National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns","Population-based Nationwide Study on Invasive Pneumococcal Infections Among Children (0-18 Years) in France","IPD","Inclusion Criteria:\n\n* Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood polymerase chain reaction (PCR).\n\nExclusion Criteria:\n\n* Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory","1 Day","18 Years",{"count":107,"type":22},2500,"After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.",[28,110,111,112],"Pneumococcal Conjugate Vaccine","Antibiotic Treatment","Mortality","RECRUITING","2026-04-23",{"date":116,"type":59},"2026-04-28",{"date":118,"type":59},"2010-12-13",{"date":120,"type":22},"2030-01-01",{"name":122,"class":66},"Association Clinique Thérapeutique Infantile du val de Marne",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100579331","phase-4-immunogenicity-and-safety-pcv-20-of-the-vaccine-administered-during-an-acute-febrile-illness-in-adults-100579331","NCT06822907","Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","Immunogenicity and Safety of the 20-Valent Pneumococcal Conjugate Vaccine (PCV-20) Administered During an Acute Febrile Illness in Adults: a Multicentric Randomized Non-inferiority Trial","PREV-HOSPIT","Inclusion criteria :\n\n* History of body temperature ≥ 38°C measured at least twice prior to randomization (Randomization must be performed as soon as possible on a febrile patient or 72 hours after apyrexia at the latest)\n* Having at least one comorbidity that defines patients as medium or high risk for pneumococcal invasive infection:\n\n  * Medium risk: Cyanogenic congenital heart disease; chronic heart failure; chronic respiratory failure; chronic obstructive pulmonary disease; emphysema; severe asthma under chronic treatment; chronic renal failure; chronic liver disease; diabetes mellitus treated; Osteo-meningeal leak or cochlear implant; Age \\> 65 years old.\n  * High risk : Hypo or asplenic people; hereditary immunodeficiency syndromes; people living with HIV; solid organ transplanted; People under immunosuppressors (corticosteroids, biotherapy) for an auto-immune or an inflammatory chronic disease; patients with nephrotic syndrome\n* Hospitalization for \\> 24 hours long\n* Social security affiliation\n* Signed informed consent\n\nExclusion criteria :\n\n* Patient unable to give informed consent\n* Curators, wardship\n* History of previous vaccination with PCV-7 or PCV-13 or PCV-20\n* History of PPV-23 in the previous year\n* Patient having received another vaccination within one month prior to inclusion or planning another vaccination in the month after inclusion except for Influenza vaccine.\n* Patient with history of bone marrow transplantation\n* Patient with haematological malignancies\n* Patient under chemotherapy for solid tumor or with a history of chemotherapy in the past three months\n* Patient treated with Rituximab currently or in the past 6 months\n* Patient with Sequential Organ Failure Assessment (qSOFA ) score ≥ 2 at randomization (acute severe febrile illness)\n* Patient hospitalized in an Intensive Care Unit\n* Pregnancy\n* Breastfeeding woman\n* Recipients of polyclonal gammaglobulins in the past three months\n* Inability to follow the protocol\n* Bleeding disorder contra-indicating intramuscular injection according to the investigator\n* History of allergy to PCV-20 or vaccine-related components.\n* S. pneumoniae infection with laboratory confirmation (blood culture, culture from a sterile site, urinary or Cerebrospinal fluid antigens, sputum culture with \\> 10\\^7 colony forming unit (CFU)\u002FmL) being the cause of the current hospitalization","85 Years",{"count":133,"type":22},1052,[135],"PHASE4","Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality. The incidence and therefore the burden of pneumococcal infections have been significantly reduced thanks to the use of pneumococcal conjugate vaccines (PCVs). PCVs were shown to be effective against vaccine-type serotypes causing both non-invasive and invasive pneumococcal diseases (IPD) in children and adults. PCVs use in children was shown to have an impact on IPD incidence among adults due to herd immunity and on antimicrobial resistance. To increase the protection of at-risk patients against IPD, the 20-valent PCV (PCV-20) is recently recommended in adults, after a period where PCV-13 followed by pneumococcal polysaccharide vaccine 23 valent (PPV-23) was recommended. PCV-20 effectiveness against IPD and against pneumonia was inferred from immunobridging with PCV-13. Indeed PCV-13 was shown effective to reduce the incidence of low respiratory tract infections and IPD (bacteraemia and meningitis) in 65-years-old-adults and older. Currently immunization against S. pneumoniae is recommended with PCV-20 for adult patients at-risk for IPD such as immunocompromised (=high-risk patients) and in immunocompetent people with underlying chronic conditions (cardiovascular, liver, pulmonary, kidney diseases and diabetes mellitus) (=medium risk patients). However, vaccine coverage against IPD in adults remains low globally, and does not exceed 5 % in France. Reducing missed opportunities of vaccination for S. pneumoniae is crucial.",[138,28],"Acute Febrile Illness",[140,141,142,143,144,145,146],"vaccin","pneumococcal","Prevenar 20","Acute febrile illness","infections","PCV-20","PCV-21","2026-03-25",{"date":149,"type":59},"2026-03-30",{"date":151,"type":59},"2025-12-17",{"date":153,"type":22},"2028-10-01",{"name":155,"class":66},"Centre Hospitalier Universitaire de Saint Etienne",24,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":16,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},"100594310","phase-3-a-study-to-evaluate-the-immunogenicity-and-safety-of-13-valent-pneumococcal-conjugate-vaccine-pcv13i-in-healthy-infants-aged-2-months-minimum-6-weeks-100594310","NCT07017777","A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","Inclusion Criteria:\n\n* Healthy infants with stable clinical conditions aged 2 months (42-90 days) at the time of screening, based on medical history and clinical assessment by the investigator. Infants will be eligible starting from the day they turn 6 weeks of age.\n* Infant's parent or legal guardian must be able and willing to provide informed consent for the infant's participation in the study.\n* Participants and their parent or legal guardian must demonstrate the ability to comply with all trial procedures and be available for the entire follow-up duration.\n* The infant's parent or legal guardian must have an easily identifiable and stable place of residence within the study area, be available for the duration of trial participation, and have access to a reliable means of telephone contact for communication with the study team.\n\nExclusion Criteria for the first dose:\n\n* Infants born at \\\u003C35 weeks of gestation.\n* Infants who have previously received any pneumococcal vaccine.\n* Infants currently participating in or who have recently participated in another interventional clinical trial.\n* Infants with an axillary temperature of ≥37.8°C at the time of enrollment (the participant must be deferred until recovery. The visit may be rescheduled when this criterion is met.)\n* Infants with any congenital abnormalities, chronic medical conditions, or genetic disorders, severe malnutrition, inherited disease and others, that in the investigator's judgment, may interfere with the study outcomes.\n* History of anaphylactic shock\n* History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the experimental and control vaccine\n* History of epilepsy and convulsions.\n* Have received immunosuppressive treatment, cytotoxic treatment, systemic steroid treatment for more than 2 weeks, etc. (excluding local treatment, surface treatment of acute non-concurrent dermatitis, or spray treatment of allergic rhinitis).\n* Received or planned to receive blood\u002Fplasma products or immunoglobulins throughout the study period or prior to study vaccination.\n* History of coagulation disorders or blood conditions that could cause anemia or excess bleeding as judged by the investigator.\n* Infants with known or suspected immunodeficiency, as determined by medical history and\u002For physical examination.\n* Administration of other vaccines within 7 days prior to enrollment.\n* Any history or current evidence of a condition or therapy that could confound study results, interfere with participation, or is not in the best interest of the participant, as judged by the investigator.\n* The participant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the contract research organization (CRO), the investigator, or study site personnel.\n* Any other condition or situation that, in the investigator's judgment, might interfere with the study or pose additional risks to the participant.\n\nIndividual termination criteria for subsequent doses:\n\n* Severe allergic reaction after the previous vaccination.\n* Serious adverse events caused by the previous vaccination that is not suitable for subsequent vaccination(s) as judged by the investigator.\n* Newly identified symptoms or newly occurred cases after the first vaccination that do not meet the inclusion criteria for the first dose, or that meet the exclusion criteria for the first dose. The decision to discontinue participation is determined by the investigator.\n* Other reasons for exclusion considered by the investigator.","6 Weeks","2 Months",{"count":167,"type":22},600,[169],"PHASE3","This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a 2+1 schedule (2 months, 4 months and 12-15 months). The trial will enroll approximately 600 healthy infants aged 2 months (at least 6 weeks) who will be randomly assigned in a 1:1 ratio to receive either the experimental or control vaccine, with 100 in each group (200 in total) randomized to subgroups and subject to additional immunogenicity assessments. All participants will be evaluated for solicited adverse events for 7 days and unsolicited adverse events for 30 days post each vaccination. Immunogenicity evaluation will be performed in all participants at baseline and post the booster dose, while the sub-cohort participants will be evaluated for post primary series immunogenicity additionally.",[28,81,82],[173,85,174,175,176,177],"PCV13i","Pneumococcal infections","2 months of age","Safety","Immunogenicity","2026-02-25",{"date":180,"type":59},"2026-02-27",{"date":182,"type":59},"2025-11-14",{"date":184,"type":22},"2028-05-15",{"name":94,"class":95},3,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":16,"sex":17,"minAge":194,"maxAge":131,"enrollmentInfo":195,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":67},"100592808","in-depth-analysis-of-the-immune-responses-in-the-upper-respiratory-tract-in-older-adults-infected-or-colonized-with-streptococcus-pneumoniae-spn-100592808","NCT06998251","In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)","NoseSpnElderly","Inclusion criteria:\n\n* Aged 60-85 years\n* Able to provide informed consent either independently or by a legal representative\n* Group 1 (Spn pneumonia patients): clinical and\u002For radiological signs of pneumonia\n* Group 1 (Spn pneumonia patients): positive Spn urinary antigen and\u002For blood culture and\u002For positive sputum test.\n* Group 2 (viral respiratory infection patients): clinical signs of a respiratory infection\n* Group 2 (viral respiratory infection patients): positive test for influenza or RSV\n* Group 3 (asymptomatic Spn-carriers): healthy without clinical signs of infection and no lower respiratory symptoms within the last month.\n\nExclusion criteria:\n\n* Immunosuppression,\n* Use of inhalation and\u002For nasal steroids the last month\n* Intubation or under invasive mechanical ventilation\n* Long-term antibiotic treatment prior to disease onset","60 Years",{"count":196,"type":22},280,"The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection. The immune response during the acute phase of the infection and after recovery will be compared to the immune response of asymptomatic Spn carriers as well as to the immune response of patients diagnosed with a viral respiratory infection (flu or respiratory syncytial virus (RSV)).\n\nThe primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with bacterial\u002Fviral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.\n\nParticipants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until discharge from the hospital or resolution of symptoms. During those visits, questions regarding symptoms will be asked.",[28,199,200],"Respiratory Syncytial Virus (RSV) Infection","Influenza Infection","2025-05-21",{"date":203,"type":59},"2025-05-31",{"date":205,"type":59},"2024-12-03",{"date":207,"type":22},"2026-11",{"name":209,"class":66},"University Hospital, Geneva",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":16,"sex":17,"minAge":164,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":186},"100562825","phase-3-a-phase-3-study-to-evaluate-the-immunogenicity-and-safety-of-minhais-pcv13-dttt-vaccine-as-compared-to-pfizers-pcv13-vaccine-100562825","NCT06608199","A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT\u002FTT Vaccine As Compared to Pfizer's PCV13 Vaccine","A Multi-center, Randomized, Blinded, Active-controlled, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Co-administered with Hexavalent Vaccine At 2, 4 and 12-15 Months of Age to Healthy Infants in Indonesia","Inclusion Criteria:\n\n1. Healthy infants based on medical history and clinical assessment.\n2. Infants age of 6-8 weeks at enrolment. Infants will be eligible since the day they reach 6 weeks of age and until 8 weeks of age included.\n3. \\*Body weight at enrollment ≥3.0 kg (If the subject does not meet the criteria, the visit may be rescheduled when the criteria is met.).\n4. \\*On the day of vaccination and within 3 days prior to 1st dose of vaccination, axillary temperatures \\<37.5°C\u002F99.1°F (If the subject does not meet the criteria, the visit may be rescheduled when the criteria is met.).\n5. Infant's parent(s) or legal guardian must be able and willing to provide voluntary written\u002Fthumb-printed informed consent for the infant to participate in the study.\n6. Infant's parent(s) or legal guardian must be willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n7. The infant's mother must provide related medical certificate(s) for the negative results for HIV, HBV and syphilis infection within 1 year prior to screening.\n8. Infant's parent(s) or legal guardian must have a readily identifiable place of residence in the study area, be available for the duration of trial participation, and have a means of telephone contact.\n\nNote: For items with an asterisk (\\*), If the subject does not meet the criteria, the visit may be rescheduled when the criteria is met.\n\nExclusion Criteria:\n\n1. Use of any investigational product other than that used in the study prior to randomization or planned use of such a product during the period of study participation.\n2. History of S. pneumoniae infection as confirmed by laboratory testing if available.\n3. The infant who are children in care, preterm and low-birth-weight (Preterm infants have a gestational age below 37 weeks at birth and low-birth-weight infants have a birth weight below 2.5 kg).\n4. History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the investigational vaccine. And\u002For all components of the hexavalent vaccine.\n5. History of anaphylactic shock.\n6. Any abnormal vital sign as judged by the investigator.\n7. \\*Participant experiences acute diseases or acute exacerbation of chronic diseases or uses antipyretic, analgesic and anti-allergic drugs (such as paracetamol, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days before vaccination.\n8. \\*History of administration of attenuated vaccines within 14 days (\\<14 days) and inactivated vaccines within 7 days (\\<7 days) prior to the 1st dose of investigational vaccine (If the participant\\[s\\] does not meet the criteria, the visit may be rescheduled when the criteria are met).\n9. Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, Neisseria meningitidis and\u002For Streptococcus pneumoniae with the exception of vaccines where the first dose can be given before 2 months of life according to the national recommendations.\n10. History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease, Neisseria meningitidis.\n11. Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥10 mg\u002Fday of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. Inhaled\u002Fnebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids within indicated dosage are permitted.\n12. \\*Administration of immunoglobulins and\u002For any blood products or anticipation of such administration within 28 days before vaccination and during the study period.\n13. History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding (e.g., thalassemia, coagulation factors deficiency, severe anemia at birth).\n14. History of suspected primary immunodeficiency.\n15. History of meningitis, seizures or any neurological disorder.\n16. A family history of congenital or hereditary immunodeficiency.\n17. The infant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the CRO, the investigator, study site personnel.\n18. Any medical or social condition that in the opinion of the investigator may compromise the well-being of the study participant, interfere with the study objectives, pose a risk to the study participant, or prevent the study participant from completing the study follow-up.\n\nNote: For items with an asterisk (\\*), if the participant meets these exclusion criteria, the visit may be rescheduled for a time when these criteria are not met.","8 Weeks",{"count":219,"type":22},500,[169],"The goal of this clinical trial is to evaluate the immunogenicity and safety of Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT\u002FTT) as compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine (PCV13) when co-administered with Hexavalent Vaccines at 2,4, and 12-15 months of age, to healthy infants in Indonesia. This study aims to demonstrate the non-inferiority of the serotype-specific immune responses elicited by the novel PCV13-DT\u002FTT (Pneuminvac) as compared to PCV13(Prevenar 13) one month after the booster dose, and evaluate the safety of PCV13 co-administrated with Hexavalent Vaccine(Hexaxim).",[223,28],"Pneumococcal Vaccines",[84,225,226,227],"Hexavalent Vaccine","Prevenar 13","Co-administration","2025-03-20",{"date":230,"type":59},"2025-03-24",{"date":232,"type":59},"2024-11-01",{"date":63,"type":22},{"name":235,"class":95},"Beijing Minhai Biotechnology Co., Ltd",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":243,"maxAge":131,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":67},"100509981","the-effect-of-audit-and-feedback-on-pneumococcal-vaccination-coverage-100509981","NCT05920499","The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage","The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage in Adults At Risk in General Practice: a Cluster Randomized Trial","Inclusion Criteria\n\n* To be eligible for inclusion in the study, general practice (GP) centers must conform to the following conditions:\n\n  1. It is a Flemish GP center in the INTEGO network.\n  2. The GP center uses an electronic health record (EHR), automatically linked to the INTEGO database.\n  3. The physician (one per center, in name of all GPs in that center) signs a specific study consent form.\n* To be eligible for inclusion in the study, patients must conform to the following conditions:\n\n  1. The patient belongs to a target group for pneumococcal vaccination (based on https:\u002F\u002Fwww.health.belgium.be\u002Fsites\u002Fdefault\u002Ffiles\u002Fuploads\u002Ffields\u002Ffpshealth\\_theme\\_file\u002Fhgr\\_9562\\_vaccinatie\\_tegen\\_pneumokokken\\_vweb.pdf):\n\n     A. Adults aged 16 - 85 years old with a high risk for a pneumococcal infection\n     * Adults with an immunity disorder\n     * Adults with anatomical and \u002F or functional asplenia, sickle-cell disease or hemoglobinopathy\n     * Adults with cerebrospinal fluid or cochlear implant leakage B. Adults (aged 50 - 85 years old) with comorbidity\n     * Chronic cardiac disease\n     * Chronic pulmonary disease or smoker\n     * Chronic liver disease or ethylabusus\n     * Chronic kidney disease\n     * Chronic neurological or neuromuscular disorders with aspiration risk\n     * Diabetes mellitus C. Healthy persons aged 65 - 85 years old\n  2. The patient has an electronic medical record (EMR) in the participating general practice centre. This EMR contains all the patient information, for instance regarding medical history and medication and is managed by the general practitioner.\n\nExclusion criteria\n\n* Patients excluded from feedback: patients not belonging to one of the target groups for pneumococcal vaccination.\n* Patients excluded from AUDIT: patients not belonging to one of the target groups for pneumococcal vaccination OR\n\n  * Correctly vaccinated high-risk patients (PPV23 less than 5 years ago AND PCV13 ever received)\n  * Correctly vaccinated adults with comorbidity (1) PCV13 ever received AND PPV23 less than 5 years ago, OR 2) PCV13 ever received AND 2x PPV23 vaccination more than 5 years ago)\n  * Correctly vaccinated healthy persons (PPV23 ever received)","16 Years",{"count":245,"type":22},36,[25],"The goal of this cluster-randomized trial is to study the effect of Audit and Feedback loops on pneumococcal vaccination coverage rate in adults at risk in general practice.\n\nThe main questions it aims to answer are:\n\n* To assess the effect of \"clinical AUDIT and feedback\" loops on the pneumococcal vaccination coverage rate in adults at risk in general practice.\n* To explore whether the increase in vaccination coverage rate after implementation of Audit and Feedback loops is different in specific subgroups (risk groups, male\u002Ffemale, age, smoking status).\n\nEvery general practice center assigned to the control or intervention group will have access to a clinical AUDIT to identify patients that may benefit from a pneumococcal vaccination. The general practice centers in the intervention group will also receive an individualized extended electronic feedback report, with multiple components like benchmarked performances and action plans, at baseline and each 2 months from baseline onwards.",[28],[250,251,252,253],"AUDIT","Feedback","general practice","pneumococcal vaccination rate","2024-09-21",{"date":256,"type":59},"2024-09-24",{"date":258,"type":22},"2025-01-31",{"date":260,"type":22},"2026-03-31",{"name":262,"class":66},"Bert Vaes",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":67},"100429726","phase-4-safety-and-immunogenicity-following-meningococcal-and-pneumococcal-immunization-among-adult-people-living-with-hiv-100429726","NCT04875819","Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV: A Single Center, Non-blinded, Randomized Clinical Trial","MENPI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Seropositive for HIV-1\n* Recipient of ART\n* Plasma HIV-RNA \\\u003C 500 copies\u002Fml\n* Patients written consent obtained\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* History of meningococcal or pneumococcal vaccination\n* Allergies towards any of the vaccine components\n* Temperature \\> 38 ᵒC\n* Sign of bacterial infection\n* Previous known or suspected disease caused by N. meningitidis\n* Active AIDS associated illness\n* Active malignancy\n* End-stage renal or liver disease\n* Bleeding disorder\n* Recipient of any blood, blood products and\u002For plasma derivatives or any parenteral immunoglobulin preparation within the last month\n* Use of immunosuppressive agents (corticosteroids, cancer chemotherapeutic agents etc.)",{"count":272,"type":22},55,[135],"MENPI is an investigator-initiated single-centre randomized controlled trial which aims to assess the efficacy and safety of meningococcal and pneumococcal vaccination in adults living with HIV receiving antiretroviral treatment.\n\nParticipants are randomized 1:1 to either a two-dose Menveo® and Bexsero® regimen or a Prevenar13®\u002FPneumovax23® prime-boost regimen at day 0 and day 60 and cross over on day 90. All participants will follow an identical follow up program including plasma collection, pharyngeal swab, and adverse event registration.\n\nImmunogenicity will be determined on venous blood sampled at 30 days post-vaccination and yearly for five years.",[276,277,28],"Hiv","Meningococcal Infections","2021-05-05",{"date":280,"type":59},"2021-05-06",{"date":282,"type":59},"2021-04-28",{"date":284,"type":22},"2026-12",{"name":286,"class":66},"Thomas Benfield"]